Cardiac biomarkers on mavacamten in nonobstructive HCM: Sub-study of the ODYSSEY-HCM trial

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

About the speaker

Doctor Milind Desai

Cleveland Clinic, Cleveland (United States of America)

11 More presentations in this session

Presentation thumbnail

Discussant - The precision care of myocardial disease

Presentation thumbnail

Finerenone in the treatment of cardiac failure in patients with hypertrophic cardiomyopathy

Doctor K. Amosova (Kharkiv, UA)

Presentation thumbnail

MYH7 and MYH6 genetic variants, clinical and bioinformatic approaches suggest shared haplotype.

Doctor G. Streitenberger (Buenos Aires, AR)

Presentation thumbnail

Genotypic and phenotypic insights into inherited heart diseases at a public hospital in Argentina

Doctor L. Gomez (Buenos Aires, AR)

Presentation thumbnail

The added value of the Greek National Network of Precision Medicine in Cardiology. Greece is a natural park of rare diseases.

Doctor E. Karvouni (Athens, GR)

Access the full session

Session thumbnail

New perspectives in cardiology (3) - The precision care of myocardial disease

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Design of ODYSSEY-HCM: a phase 3 randomized placebo-controlled study to assess the efficacy and safety of mavacamten in patients with nonobstructive hypertrophic cardiomyopathy

Congress Presentation

Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial

Congress Presentation

Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources